As population’s age and the incidence of chronic disease continues to rise, governments and other payers are looking for solutions to make healthcare expenditures sustainable. However, instead of biopharmaceuticals being viewed as one of the most efficient and cost-effective solutions to this looming healthcare crisis, many biopharma therapies – and the companies that make them – are often viewed as one of the main factors contributing to an affordability crisis. To alter this public impression, biopharma companies will need to work with payers, providers, patients and policymakers to develop new models that focus on and recognize value.
The historical biopharmaceutical pricing model which relies on government-driven, unit-based pricing may be too one-dimensional for the current needs of the marketplace. During this Super Session, a panel of healthcare stakeholders will discuss the biotechnology industry’s hot button pricing issue and innovative solutions that reward improved health outcomes.
Session ID: 13460